Answers are grounded in this paper and cite their sources.
HBsAg-1018 had a similar safety profile to HBsAg-Eng. With improved immunogenicity and fewer doses over a shorter time, HBsAg-1018 has the potential to provide improved seroprotection and a significant public health benefit to adults 18 years of age or older.
No takes yet. Share an insight, caveat, or question.
Hyer et al. (2018) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: